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Patient 1. A 39-year-old male farmer was admitted to the Department of
Nephrology of the Hippokration University General Hospital because of
the acute onset of oliguria, hematuria, hematemesis, and melena. One
week prior to admission, he visited his local physician at a village outside
Thessaloniki complaining of fever up to 40°C, chills, headache, weakness,
dizziness, myalgias, and arthralgias. Paracetamole and amoxicillin, 2 g/day,
were prescribed. Three days later he developed generalized stiffness,
backache, anorexia, nausea, vomiting, hiccups, abdominal pain, and
diarrhea. On physical examination the patient appeared acutely ill, with
injection of conjunctivae and pharynx. The temperature was 37.2°C; blood
pressure, 90/70 mm Hg; and pulse rate, 58 beats/mm. On the sixth day he
developed gross hematuria, hematemesis, and melena; on day 7 he was
admitted to this hospital.
On admission he was confused and edematous. The blood pressure
ranged between 120/70 mm Hg and 170/80 mm Hg. The temperature was
36.8°C and pulse rate was 70 beats/mm. Physical examination revealed no
abnormal findings of the skin, lungs, heart, and abdomen. The 24-hour
urine volume was 400 ml. Laboratory investigations showed: hemoglobin,
10.2 g/dl; hematocrit, 31%; white blood cell count, 14,200/mm3, with 86%
polymorphonuclear leukocytes, 10% lymphocytes, and 4% monocytes;
and platelet count, 120,000/mm3. The blood urea level was 278 mg/dl;
serum creatinine, 9.4 mg/dl; SGOT, 51 lU/liter; SGPT, 34 lU/liter; y-GT,
14 U/liter; total protein, 4.9 g/dl; total calcium, 7.1 mg/dl; sodium, 134
mEq/liter; potassium, 4.0 mEq/liter; bicarbonate, 17 mEq/liter; and total
bilirubin, 1.2 mg/dl. Urinalysis revealed red blood cells too numerous to
count and protein (800 mg/liter). The antinuclear, antimitochondrial, and
anti-smooth muscle antibody titers were borderline positive. The C3 and
C4 were normal, as were serum IgG, 1gM, and IgA levels; the C-reactive
protein was 1.68 mg/dl (upper limit of normal, I mg/dl). Coagulation
studies demonstrated positive fibrin degradation products (1:32), and
The Nephrology Forum is funded in part by grants from Amgen,
Incorporated; Merck & Co., Incorporated; Marion Merrell Dow, Incor-
porated; Dialysis Clinic, Incorporated; and R & D Laboratories.
© 1995 by the International Society of Nephrology
prolongation of partial thromboplastin time (33 sec/90 see), which was
reversed after the first three days of hospitalization. A chest radiograph
showed Kerley B lines most prominent in the lower and mid-lung fields.
Blood and urine cultures were sterile. Ultrasound examination demon-
strated a kidney length of 13.5 cm bilaterally without evidence of
obstruction. The renal biopsy included 20 glomeruli, which were relatively
well preserved. Interstitial hemorrhage, edema, and inflammatory infil-
trate of lymphocytes and monocytes were present (Fig. 1). Immunofluo-
rescence microscopy showed mild focal 1gM deposits in the renal tubules.
A serologic test for leptospirosis was negative. Indirect immunofluores-
cence study for Hantaan virus was positive (IgG 1:1024, 1gM 1:2048).
The patient was hemodialyzed every day (4-hour sessions) for 3
consecutive days. The urine volume increased to 4 liters after eight days of
hospitalization. He was discharged on the 10th day with a serum creatinine
of 2 mg/dl; blood urea, 66 mg/dl; and hematocrit, 37%. One year later, the
patient was in excellent condition. Renal function studies and other
hematologic and biochemical tests were within normal limits.
Patient 2. A 24-year-old male woodcutter was transferred to the
Department of Nephrology of the Hippokration University General
Hospital from a peripheral hospital because of oliguria and acute uremia.
Ten days previously he had had abdominal pain and fever. He took
antibiotics without consulting a physician, and the symptoms subsided in
three days. One day later, however, he experienced hematemesis, melena,
abdominal colic, hematuria, and oliguria. The patient was admitted to a
peripheral hospital. The only data available from that admission revealed:
white blood cell count, 16,000/mm3 (polymorphonuclear leukocytes 68%,
lymphocytes 28%, monocytes 4%); hematocrit, 44%; and 3+ hemoglo-
binuria. Two days later the patient developed epistaxis and a bloodshot
right eye, and was transferred to this hospital.
On examination, the temperature was 37.2°C; blood pressure, 130/80
mm Hg; pulse rate, 80 beats/mm; white blood cell count, 11,000/mm3
(76/23/1%); hematocrit, 29%; platelets, 120,000/mm3; blood urea, 320
mg/dI; serum creatinine, 7.4 mg/dI; plasma potassium, 3.2 mEq/liter;
plasma sodium, 130 mEq/liter; and orate, 17 mg/dl. Coagulation studies
were within normal limits. The 24-hr urine volume was 150 ml; many red
cells were present in the urine, and urinary protein was 450 mg/liter. Blood
and urine cultures were sterile, antibody titers for several infectious
diseases were negative, except for elevated levels of IgG (1:5 12) and 1gM
(1:4096) antibodies for Hantavirus. Peritoneal dialysis was started on the
second hospital day and continued for six days.
Renal biopsy showed interstitial edema, distended lumina, epithelial
flattening, and interstitial inflammatory cell infiltrates (Fig. 2). Immuno-
fluorescence showed mild focal 1gM deposits in the renal tubules and the
glomerular mesangium.
Renal function gradually improved and the patient was discharged on
the 40th day after admission. His condition was satisfactory; hematocrit,
32%; blood urea, 58 mg/dl; and plasma creatinine, 2.4 mg/dl.
Ten years later the patient was readmitted to the hospital because of
high blood pressure, which had been discovered six months earlier. He had
been working full time and had no medical complaints. The plasma
creatinine was 1.9 mg/dl; blood urea, 69 mg/dl; and hematocrit, 52%; 1gM
antibody for Hantavirus was negative, but the IgG antibody was positive at
1:512. Renal size was slightly reduced bilaterally.
A second renal biopsy showed completely solidified glomeruli in focal
areas and fibrous thickening of the intima of small arteries (Fig. 3).
Immunofluorescent examination showed mild focal 1gM and C3 deposits,
which were granular in character, in the renal tubules and the mesangium.
Nifedipine, enalapril, and a low-salt diet controlled his blood pressure. In
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Fig. 1. Acute interstitial nephritis with
inflammatory cell infiltrate and edema in a
patient with HFRS (Patient 1). (Hematoxylin-
eosin X 100.)
Fig. 2. Epithelial flattening, distended lumina,
and inflammatory cell infiltrates (Patient 2).
(Hematoxylin-eosin X 100.)
addition, a 40 g protein diet was prescribed to keep his blood urea near
normal.
Discussion
DR. MENELAOS PAPADIMITRIOU (Associate Professor of Medi-
cine and Nephrology, and Director, Department of Nephrology
and Artificial Kidney Unit, Aristotelian University, Hippokration
General Hospital, Thessaloniki, Greece): The first patient, a
39-year-old farmer, was admitted to the Hospital because of
gastrointestinal hemorrhage, hematuria, and evidence of acute
renal failure. These complications appeared after a flu-like
illness, when the patient became hypotensive and confused.
Anemia, thrombocytopenia, the presence of fibrin degradation
products, and prolongation of partial thromboplastin time
suggested disseminated intravascular coagulation. In addition,
acute renal failure with rising blood urea and serum creatinine
values, together with mild proteinuria and macroscopic hema-
tuna, contributed to the severity of the disease and to the
gradual clinical deterioration of the patient. As he was from an
area where sporadic cases of acute renal failure due to
hemorrhagic fever with renal syndrome (HFRS) had been
described in the recent past, serum samples were sent to the
laboratory for detection of antibodies to the Hantaan-like
viruses. The results showed very high titers of 1gM- and
IgG-specific antibodies. The patient was dialyzed during the
oliguric phase and, after correction of his coagulation abnormalities,
a renal biopsy was performed. Histologic examination of the
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Fig. 3. Glomendi completely fibrosed and
intimal fibrous thickening with nairowing of the
lumen of small arteries (Patient 2).
(Hematoxylin-eosin x 100.)
tissue showed reversible changes affecting mainly the renal tu-
bules, the interstitial tissue, and the renal medulla, that is, all the
features defining acute interstitial nephritis. The patient had no
allergic skin lesions, and serologic testing for leptospirosis was
negative. Other causes of acute interstitial nephritis were there-
fore easy to exclude [1]. The patient was discharged 10 days after
admission. One year later, he was in excellent condition, and
hematology and biochemistry data were within normal limits. This
case clearly illustrates that HFRS can cause a reversible form of
acute renal failure [2].
The second patient, a 24-year-old woodcutter, was referred to
this Department from a peripheral hospital 10 days after the onset
of symptoms of HFRS. At discharge, his serum creatinine was 2.4
mg/dl. Unfortunately, there are no medical data available for a
period of 10 years, until the patient reappeared and was found to
have hypertension and mild renal insufficiency. The renal histol-
ogy showed focal areas of solidified glomeruli and intimal thick-
ening of small arteries. This case suggests the possibility that
chronic renal disease might develop as a long-term consequence
of HFRS.
History
An acute febrile nephropathy, HFRS is caused by closely
related zoonotic viruses in the family Bunyaviridae [3]. The
modern history of hantavirus infection and nephropathy started
during the Korean war, when several United Nations troops
developed an illness characterized by high fever, severe headache,
muscle pain, and hemorrhage. A high percentage of these patients
had acute renal failure; approximately 7% died. In three years,
some 3000 soldiers were diagnosed as having Korean hemorrhagic
fever with renal syndrome [4]. Experienced western virologists
later began to realize that similar hemorrhagic fevers were
prevalent outside southeast Asia. They detected similarities be-
tween Korean hemorrhagic fever and illnesses such as Tula fever
in Russia and a mild form of a similar disease in China. In fact,
more than 100,000 cases were reported annually in China alone
[4—6]. In addition, in 1953 National Institutes of Health virologist
Table 1. Recognized hantaviruses (January 1994)
Reservoir Virus Disease Distribution
Striped field mice Hantaan HFRS Asia
Rats Seoul HFRS Cities worldwide
Bank voles Puumala Nephropathia
epidemica
Northern and
central Europe
Yellow-necked
mice
Belgrade/Porogia HFRS Balkan countries
Meadow voles Prospect Hill — USA
Shrews Tottapalayam — India
Bandicoots Thailand — Thailand
D. Carleton Gajdusek, then with the U.S. Army, proposed a
similarity between the Asian hemorrhagic fever and nephropathia
epidemica, a mild renal disease first seen in Scandinavia [4].
In 1978, the pioneering work of the virologist H. W. Lee of the
Korean University College of Medicine in Seoul was published.
He isolated a virus from striped field mice (Apodemus agrarius)
captured near the Hantaan river in South Korea [7]. Antigens
from the lung of rodents roaming around the Hantaan river
reacted with the serum of patients who had suffered from Korean
hemorrhagic fever. All viruses of this genus have resisted culturing
in the laboratory. Not until 1981 did army virologist George
French, together with H. W. Lee and other colleagues, cultivate
the virus to which a new niche was assigned within the Bunyaviri-
dae family [4]. Researchers quickly flushed out other similar
hantaviruses (Table 1).
In 1982, a team headed by Dr. Gajdusek isolated a hantavirus
from meadow voles (Microtus pennsylvanicus) in Frederick, Mary-
land. They called the virus Prospect Hill, but it could not be linked
to any human disease [4, 8]. Later that year, Lee isolated from rats
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Table 2. Prevalence (%) of clinical and laboratory findings, and
prognosis in patients with different types of HFRS
Puumala Hantaan
Korea
Seoul
Korea
Porogia
GreeceFrance Sweden Finland
(23) (24) (9) (25) (25) (26)
Number of 320 355 78 229 40 138
patients
Males 83 72 80 68 75 85
Fever 97 94 100 100 100 100
Headache 79 45 90 84 45 75
Abdominal pain 75 48 84 79 72 —
Backache 63 66 82 80 53 59
Nausea 59 — 78 79 48 —
Vomiting 55 33 70 70 59 71
Acute myopia 36 7 12 48 9 —
Per > 1 mgJdl 97 99 86 42 92 100
Thrombocytopenia 68 62 57 96 80 37
Leukocytosis 61 — 57 91 75 50
Transaminasemia 42 — 52 91 22 —
Proteinuria 84 89 100 100 100 100
Hematuria 57 73 74 85 — 100
Dialysis 7 — 2 40 30 30
Mortality 0 0 0 2—7 0 9
(Rattus norvegicus) in Seoul a hantavirus that causes a mild form
of HFRS. This finding led researchers to believe that rats on
trading ships had dispersed hantaviruses worldwide. Indeed, the
Seoul serotype appears to cause much of the HFRS in China [5,
6]. In 1985 a group led by microbiologist Ted Tsai of the U.S.
Centers for Disease Control and Prevention found in New
Orleans rats a virus similar to the Seoul serotype, which they
labeled Tchoupitoulas. After that, Tsai said, "Virtually everywhere
we looked—west coast, east coast, Cincinnati, New York
City—we found infected rats [4]."
Later in 1985, a research team led by virologist Joel Dairymple
at the U.S. Army Medical Research Institute of Infectious Disease
(USAMRIID) isolated from bank voles (Chlethrionomys glareo-
lus) in Sweden the Puumala serotype, tentatively identified five
years earlier by Finnish researchers [9], that causes nephropathia
epidemica [10]. Other hantaviruses, still poorly characterized,
have been isolated from a patient in Greece and subsequently
named the Porogia virus [11], a house mouse in Texas, house
shrews (Suncus murinus) in India, bandicoots (Bandicota indica)
in Thailand [4], and yellow-necked mice (Apodemus flavicollis) in
the former Yugoslavia [12]. These viruses are maintained in
nature through asymptomatic infections in rodents. Humans are
infected when they come into contact with aerosols of rodent
secretions; there is no known transmission between humans [I].
Clinical picture
Hantaviruses produce a spectrum of illnesses with specific
manifestations depending on the particular virus involved. Han-
taan virus causes the most, and Puumala virus the least, severe
disease [3, 13, 14]. Seoul virus produces disease of intermediate
severity that is associated with more hepatic involvement than that
noted in other hantavirus illnesses. Prospect Hill virus has not
been identified as a human pathogen [5].
The clinical manifestations of HFRS comprise the triad of
fever, hemorrhage, and renal failure (Table 2) [15, 161. The illness
has a complex course with five recognized phases: febrile, hypo-
tensive, oliguric, diuretic, and convalescent [2, 17, 18]. Any
attempt to explain the pathophysiology of this syndrome must
take into account this complex course. The major signs and
symptoms typically seen in the course of the disease are: fever,
shock, renal impairment, relative hypervolemia, and fluid and
electrolyte imbalance [3]. In addition, most patients have a
characteristic facial flushing, which is especially visible along the
neck [5]. A petechial rash usually occurs, but it often is limited to
the axilla. An additional hemorrhagic sign, ecchymosis, is fre-
quently seen in severely ill patients. Scleral injection (bloodshot
eyes) is not uncommon [51 Most of the clinical characteristics of
the disease, however, are due to the marked and characteristic
damage to the renal medulla. This damage can progress to renal
failure and to death if patients are not dialyzed [1, 5, 19].
The most pronounced morphologic alterations in the kidneys of
patients dying of HFRS occur in the medulla, an area that is
particularly susceptible to ischemia because of low ambient P02
levels and the oxygen demand associated with solute reabsorption
[20]. In HFRS, as in other conditions associated with acute renal
failure, it is likely that reduced blood flow in medullary vessels
leads to the development of regional ischemia, thereby producing
ischemic injury to renal tubular cells. How this injury leads to
decreased glomerular filtration is uncertain, but several mecha-
nisms have been postulated, including simple obstruction of
tubular lumina by sloughed epithelium, back-leak of glomerular
filtrate due to lack of epithelial integrity, and tubuloglomerular
feedback. The last is a regulatory mechanism that lowers the
glomerular filtration rate in response to increases in the volume or
solute concentration of filtrate delivered to the macula densa.
Failure of the renal tubules to reabsorb sodium as a result of
ischemic injury is one possible trigger of tubuloglomerular feed-
back, leading to constriction of glomerular vessels and a decline in
the glomerular filtration rate [17] (Fig. 4).
The infection starts abruptly with fever, followed by loin and
abdominal pain. Concomitantly, the platelet count falls, the serum
creatinine rises, and proteinuria and/or hematuria appear. Oligu-
na is followed by a polyuric phase. Settergren et al have combined
these various features to provide a diagnostic score [14]. Fhe
clinical diagnosis is made if four or more of six criteria are present.
These criteria are: abrupt onset of fever, abdominal or loin pain,
headache, elevated serum creatinine, proteinuria and/or hematu-
na, and polyuria. In a study of more than 1000 patients, the
sensitivity of this approach reached 97% with a specificity of 93%.
I doubt that the results of this retrospective analysis will be
confirmed in a prospective study.
In Europe at least, hantavirus nephropathy should be differen-
tiated from two other forms of acute renal disease [1]. One is that
induced by nonsteroidal anti-inflammatory drugs (NSAIDs). The
typical story is of a patient with fever who takes the drug and
develops a hypersensitive acute interstitial nephropathy. To dif-
ferentiate this disease from hantavirus nephropathy, it is impor-
tant to remember that loin pain appears after NSAID intake,
there are no signs of central nervous system involvement, and
neither thrombocytopenia nor hemorrhagic symptoms occur (Ta-
ble 3). The other confounding diagnosis is leptospirosis with acute
renal failure, called Weil's disease. This diagnosis rests on the
patient's history of contact with ponds or rivers. The patient with
leptospirosis usually presents with an acute distress syndrome
accompanied by severe jaundice, symptoms unlike manifestations
of the European form of hantavirus nephropathy. Finally, serol-
ogy establishes the diagnosis [1].
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Table 3. Differential diagnosis of hantavirus nephropathy
AIN
due to
Hantavirus Leptospirosis NSAIDsa
Fever + +++
CNS involvement —
Jaundice — + + + —
Thrombocytopenia + + + —
Conjunctival hemorrhage + + —
AIN, acute interstitial nephritis; NSAIDs, nonsteroidal anti-inflamma-
tory drugs.
Whatever the significance of these diagnostic tools, it is obvious
that the northern European form of the disease is much milder
than that observed in Asia [3]. On the other hand, the rather high
mortality rate seen in Greece is attributed to the inclusion in the
statistical analysis of the most severe cases that require dialysis
and are reported by the hospitals. In addition, the Puumala type
of virus, which causes the mildest form of the disease, is not
encountered in Greece. Korean hemorrhagic fever is accompa-
nied by a much higher incidence of hypotension and shock, by the
presence of lung involvement—as evidenced by dyspnea and
pulmonary infiltrate—and by a much more severe thrombocyto-
penia. The mortality ranges from 5% to 10%, in sharp contrast to
the virtual absence of mortality in the western, northern, and
central European form of hantavirus infection [21, 22].
The prevalence of the various clinical and laboratory features of
the disease is compared in Table 2, which summarizes data from
France [23], Sweden [24], Finland [9], Korea [25], and Greece
[26]. The prevalence of the disease in males is almost exactly the
same in all series, reaching a high of 85%. This high percentage
might be due to the fact that males are involved in farming,
woodcutting, and other occupations in the open country near the
infected rodents. Fever occurs almost 100% of the time in all
series. Headache, abdominal pain, backache, and gastrointestinal
symptoms present with a prevalence ranging between 50% and
90%. Blurred vision does not regularly occur in Sweden or in the
Balkan countries [11.
Fever is associated with an intense, acute-phase reaction asso-
ciated with elevated fibrinogen levels, accelerated erythrocyte
sedimentation rate, leukocytosis, and elevation of a2-globulin
levels [3]. Again, the prevalence of these abnormalities is virtually
the same throughout Europe, but leukocytosis is higher in Korea.
Laboratory features demonstrating thrombocytopenia, mild ele-
vatiOn of serum transaminases, and renal involvement are equally
frequent in Scandinavia and western Europe. It is worthwhile to
note that hantavirus in Korea produces a higher percentage of
hepatic involvement as compared with the Seoul virus cases [25].
In Greece, the hepatic involvement is infrequent and usually mild,
as compared with Weil's disease [27, 28]. The need for dialysis is
higher in Korea and in Balkan countries. The disease almost
always runs a mild course. Oliguria is replaced by polyuria within
a few days, proteinuria usually disappears within one week, and
Injury to renal vasculature
Intravascular
coagulation Medullary ischemia
Backleak
4 Systemic hypotension +—
1
_________________________
—+ Tubular injury/\
Obstruction Tubuloglomerular
feedback
Reduced glomerular
filtration rate Decreased cardiac 4—
'l' \\\ output
Azotema 1 Glomerular injury 4
P
ARDS hypoxia
Increased sodium
excretion
Water and sodium
depletion
Fig. 4. Parhogenetic mechanisms of renal injury
in patients with HFRS.
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serum creatinine returns to normal values within 12 weeks [3];
virtually no death has been recorded, at least during the acute
phase of the disease, in patients with nephropathia epidemica [9,
29].
The widespread nature of hantavirus nephropathy should not
be obscured by the fact that the infection is often very mild and
sometimes asymptomatic. There is indeed an occasional discrep-
ancy between the prevalence of elevated antibody levels in the
population and the annual incidence of clinical reports of hanta-
virus infection. In Belgium, for example, the prevalence of
antibodies among blood donors is 1.6%, although less than 30
clinical cases of hantavirus infection have been identified over
eight years [30]. This discrepancy suggests either that the clinical
disease is not suspected and therefore not diagnosed, or the
existence of very mild forms of infection that escape detection [3].
A similar variability in the severity of the disease induced by a
single hantavirus strain is reported in Hantaan virus infection.
Thirty percent of the patients run a mild clinical course, 50% a
moderate one, and only 20% a severe course [21]. Similarly, in
laboratory-acquired infection, seropositive patients usually do not
remember a clinical episode of the disease. The reasons account-
ing for such differences in the clinical expression of an infection
induced by the same virus remain to be determined [3].
The pattern of antibody reaction, at least in one series of 76
Belgian and French patients, discloses a rise in IgG antibody level
in 85% within three weeks that is sustained for as long as 15 years
[30]. Interestingly, antibody titers are significantly higher against
the anti-Puumala strain than against the Hantaan virus in most
cases [211. The long-term persistence of high antibody levels
should be taken into account when the disease is suspected in an
endemic area. It is thus apparent that the Puumala strain is often
the cause of the benign form of hantavirus nephropathy observed
in Europe [3, 9, 13].
The benign form of hantavirus infection is known to have
co-existed in Europe with a more severe form [31]. However, until
a few years ago, epidemiologic studies including serologic data
were not readily available. A more severe form of the disease has
been found in the last decade in the former Yugoslavia, Albania,
Bulgaria, and Greece [5, 32—35]. Detailed serologic evaluation has
demonstrated the coexistence in this area of two different types of
hantavirus, one of which is identical with the Puumala strain and
another one related to, but definitely different from, the Hantaan
virus called the Fojnica virus [36]. The Fojnica strain probably is
the same as the Porogia strain recognized in northern Greece and
is perhaps related to the Maaji strain [21]; the Porogia strain is
probably responsible for the more severe form of hantavirus
infection. The Puumala and the Porogia virus each has its own
animal reservoir, mainly the Clethrionomys glareolus for the
former [36] and the Apodemus flavicollis for the latter [11]. A
recent outbreak of severe HFRS was reported from Pazarevac,
Serbia [37]; rodents were captured from this area and a hantavirus
POZ-Ml was isolated from lung tissues of hantavirus-antigen-
positive Mus musculus. Serology and restriction enzyme digestion
of polymerase chain reaction-amplified segments from this virus
showed that it was a strain of Puumala (PUU) virus. Thus, it
seems that this subgroup of PUU viruses is a significant cause of
human morbidity and mortality from HFRS in the former Yugo-
slavia and perhaps elsewhere.
Hypoproteinemia possibly due to protein leakage through the
vessel wall [2] and high levels of serum lactate dehydrogenase (an
indicator of cell death) are important indicators of the severity of
disease [251. Our experience shows that when hypotension and
vascular dysfunction are manifested early in the course of disease,
the likelihood of developing major clinical problems rises to 50%
[26]. In addition, elevated levels of specific 1gM have been
reported in patients with more severe disease [38], while leuko-
cytosis, ESR, and hematuria correlate with the highest serum
creatinine as an index of the severity of the disease [19].
Vascular dysfunction. Shock occurs among 28% of the patients
admitted to hospital in our experience [261. Capillary dilation and
congestion reflect the impairment of vascular tone; retroperito-
neal edema and collection of free fluid in the interstitial space and
pleural, pericardial, and peritoneal effusions reflect the vascular
leak. Increased vascular permeability was documented directly
more than 40 years ago by tracer studies of blood and plasma
volume [39].
As Figure 4 illustrates, the first hemodynamic effect in HFRS is
a decline in peripheral vascular resistance [18], which is tempo-
rarily offset by an increase in cardiac output. In some cases,
though, a gradual decrease in cardiac output is observed that is
not compensated for by vasoconstriction. Depending on the
extent of the vascular lesion, the blood pressure falls to hypoten-
sive levels and, in severe cases, shock ensues [2]. Potential
mediators such as prostaglandins, leukotrienes, platelet activating
factor (PAF), interleukins, interferons, TNF-a, histamine, and
bradykinin might contribute to the vascular changes I have
described [17]. More recently, nitric oxide (NO, or EDRF,
endothelial relaxing factor) has been proposed as a mechanism
contributing to the severe vasodilation and profound hypotension
in patients with the disease [40]. Hemoglobin, which might be
released from lysed erythrocytes in nephropathia epidemica,
inactivates NO and leads to the increased release of ET-1
observed in these patients [40].
In conclusion, the central physiologic derangement in HFRS is
widespread vascular dysfunction. The systemic manifestations of
this dysfunction lead to hypotension and shock, which has the
features of distributive shock [2]. The kidney is affected much
more frequently as compared with other organs in which viral
antigen has been found in fatal cases of the disease, that is, in the
endothelium of small vessels in the brain, lungs, heart, and liver
[41]. This means that the virus has no particular predilection for a
given vascular bed. The greater incidence of renal damage simply
reflects the fact that the surface of the renal vascular bed is larger
(per gram of tissue) as compared with that in other organs.
Renal dysfunction. Renal function in the initial phase of HFRS
is unimpaired. The renal plasma flow (RPF) and glomerular
filtration rate (GFR) are normal or somewhat increased during
the febrile phase. During the hypotensive and oliguric phases,
both RPF and GFR markedly decline, with a more pronounced
effect on GFR and thus a decreased filtration fraction [2]. In
parallel with these changes, proteinuria increases, serum creati-
nine and BUN rise, and urine volume falls [15, 16]. Impaired
tubular function is reflected in a loss of urinary concentrating
ability and decreased sodium reabsorption together with the
increased excretion of f32-microglobulin. The urinary protein
excretion results from tubular injury but, as it is nonselective, also
can reflect glomerular injury [2]. In fact, in a recent well-
documented series of patients with nephropathia epidemica in
Finland [19], renal biopsy findings disclosed mesangial hypercel-
lularity and sclerosis in 20 and 8 of 86 cases, respectively.
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With the onset of diuresis, RPF and GFR begin to improve, and
azotemia reverses rapidly. Full recovery of renal function takes
months, and tubular function is the last to recover. As might be
expected, recovery takes longest in persons with the most severe
degree of renal failure [21.
The same disturbance of vascular function that gives rise to
hypotension and shock in HFRS appears to account for renal
failure through its local effects on renal vasculature. Although
hypotension can worsen the degree of renal failure, severe renal
compromise occurs in patients who do not develop hypotension or
shock [26, 28]. Thismeans that possibly Hantavirus exerts its effect
directly or via an immunologic mechanism (Figs. 4 and 5). For
example, in Korean hemorrhagic fever, renal tubular dysfunction
and varying degrees of renal impairment are major clinical
manifestations that occur later in the course of the disease. In
renal biopsies performed between the 5th and 30th days after
onset of fever, viral glycoproteins were localized in the cytoplasm
of the sloughed tubular epithelial cells [42]. These findings suggest
direct invasion of the renal tubule by the virus and might partly
explain the pathogenesis of acute renal failure in Korean hemor-
rhagic fever. On the other hand, renal tubular dysfunction is also
seen in patients with nephropathia epidemica, in which hypoten-
sion and hemorrhage are rare [301.
Bleeding diathesis. Hemorrhagic complications occur to some
degree in almost all patients with HFRS and remain an important
cause of death (Fig. 6) [17]. Some of these simply reflect intense
vascular congestion and dilation, but others involve intravascular
activation of coagulation pathways and deficits in platelet number
and possibly function [2]. Thus, some of the hemostatic problems
are direct consequences of vascular endothelial injury. Morpho-
logically, this injury includes edema of the vessel walls and
increased cellularity of the endothelium. Electron microscopy
shows swelling of endothelial cells with exposure and disruption of
basement membrane together with damage of smooth muscle
[43]. Platelet and fibrin thrombi inside and outside vessel walls
indicate that activation of coagulation pathways has taken place,
as in cases of secondary hemolytic-uremic syndrome [44].
The fall in the number of circulating platelets can be dramatic
[45, 46]. It results from increased platelet consumption, as evi-
denced by decreased platelet survival time and an increased
number of megakaryocytes in the bone marrow [47]. Potential
mechanisms of thrombocytopenia include immune pathways lead-
ing to vascular injury and intravascular coagulation. The immune
complexes that have been found on platelet surfaces [48] lead to
platelet aggregation, lysis of platelets by complement, and their
phagocytosis by monocytes [491. In addition, vascular injury leads
to exposed subendothelial connective tissue and to platelet aggre-
gation and adherence [50]. Finally, platelet adherence to endo-
thelial cells is increased markedly when these cells are infected by
virus [51].
Another cause of thrombasthenia is uremia, as hemorrhage is
most pronounced during the oliguric phase of HERS. As I noted
previously, loss of endothelium due to vascular injury leads to
exposure of underlying connective tissue, which provides a surface
for activation of Factor XII. Thrombin is then generated via the
intrinsic coagulation cascade. Tissue factor expression on the
surface of endothelial cells can cause activation of the extrinsic
coagulation pathway as well [2]. Endothelial cells produce tissue
factor in response to IL-i and TNF, but whether tissue factor is
elaborated by monocytes, as in gram-negative sepsis [52], is
unknown.
Disseminated intravascular coagulation (DIC) is a common
occurrence in HFRS, and the co-existence of shock increases its
severity. Some data suggest that DIC increases the risk of
hemorrhage, and its incidence increases as the disease becomes
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Fig. 6. Pathogenesis of hemorrhage in patients with HFRS.
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more severe [53]. In fact, the long-term complications of the
disease, such as the possible appearance of arterial hypertension
and some degree of chronic renal failure, could easily be attrib-
uted to the intravascular coagulation in the kidney during the
acute phase of the disease. This unfortunate long-term complica-
tion is reminiscent of the partial cortical necrosis seen in acute
renal failure due to gram-negative sepsis and probably is more
related to DIC than to Hantavirus nephropathy per Se.
Immunology
The possibility that HFRS is an immunologically mediated
disease needs some discussion. Renal biopsies from patients with
Korean hemorrhagic fever showed direct invasion of renal tubules
by the virus [42, 54]. In fact, staining of the sections with the
avidin-biotin-peroxidase complex method with monoclonal anti-
bodies to GI and 02 envelope glycoproteins localized the viral
glycoproteins in the cytoplasm of the tubular epithelial cells
focally [421. By thin-section immuno-electron microscopy, the
occurrence of Hantaan virus-like structures were detected in the
kidneys of patients who died during the acute phase of HFRS [541.
In addition, immune-gold colloidal labeling revealed great quan-
tities of electron-dense deposits partly labeled by HFRS conva-
lescent serum. These deposits might represent antigen-antibody
complex precipitates at the level of basement membrane and
suggest that an immune-mediated process plays some role in the
pathogenesis of this disease [51.
Antibody specific to the viral antigen can be detected close to
the onset of symptoms of HFRS. In fact, a vigorous response can
be considered a marker of more severe disease; this pattern is
completely different as compared with other viral hemorrhagic
fevers [38]. Also, T-cell activation occurs very early in the course
of HFRS [55] and is associated with an absolute increase in the
number of neutrophils, monocytes, B-cells, and CD8 + (suppres-
sor) T-cells. The number of helper (CD4 +) T-cells does not
increase; thus a decrease ensues in the helper/suppressor ratio [2].
Finally, natural killer (NK) cells do not increase in number, but
their activity against tumor cells is greatly increased [56]. In
addition, virus has been cultured from B-cells and monocytes but
not from T-cells [57]. Therefore, T-cell activation is a response to
infection of other cell types rather than a consequence of direct
viral infection.
Several pieces of evidence support a role for immune com-
plexes among possible mechanisms for mediating the disease. In
HFRS immune complexes have been demonstrated in serum
[58—62], on the surface of red cells and platelets [48, 63], in
glomeruli [43, 64], in renal tubules [42, 54], and in urine [62]. In
fact, biopsies of petechial lesions have shown erythrocytes and
platelets passing through the walls of vessels containing immune
complexes [2]. Finally, in patients with nephropathia epidemica,
immune complexes have been found in renal tubular cells and the
interstitium [65].
Activation of both the classic and alternative complement
pathways also has been found in HFRS [66—68]. This activation is
greatest in severely ill patients who have the most severe vascular
injury. Thus the degree of activation peaks in the hypotensive
phase, during which the concentration of immune complexes is
highest and the systemic vascular leak more accentuated. By
activating complement and by triggering mediator release from
platelets and inflammatory cells, immune complexes can produce
the vascular injury that is the hallmark of the disease [69]. In
addition, in the presence of the specific IgE, which has been found
in high titers as early as in the febrile phase, immune complexes
also could trigger mediator release from basophils and tissue mast
cells [70] (Fig. 5).
Despite these supportive data, the immunologic findings in
HFRS differ in certain aspects from those of a classic immune-
complex disease. The typical clinical findings of an immune-
complex disease such as urticaria, serositis, and synovitis are not
frequently seen in HFRS [2, 71, 721. In addition, while mononu-
clear cell infiltrates can be found in organs, such as the liver and
spleen, perivascular infiltrates of these cells are scanty. Neutro-
philic infiltrates are not seen, except for eosinophilic granulocytes
in some cases [73, 74]. Finally, some investigators have even
suggested that HFRS is primarily an allergic disease. They
reached this conclusion based on the early appearance of specific
IgE, the presence of IgE immune complexes, and the beneficial
effects of therapy aimed at inhibiting allergic pathways [75, 76].
Management
The patient with HFRS should receive all the appropriate
measures to maintain cardiovascular stability [1, 2, 17]. Patients
already in the oliguric phase of established acute renal failure
should be carefully monitored for the possibility of water, elec-
trolyte, and acid-base imbalance, which must be promptly cor-
rected.
Vasoactive agents should be used in cases of shock after
correction of the volume deficit. If pulmonary edema is present,
the use of forced diuresis by administering furosemide and/or
vigorous ultrafiltration or CAVH dialysis can be life-saving. The
possibility of the sudden appearance of life-threatening gastroin-
testinal bleeding should always be kept in mind [15, 16]. In that
case, blood transfusions and the use of antagonists of the H2
receptors are indicated as general emergency procedures. In case
of DIC, fresh plasma infusions and/or plasma exchange treatment
are not always effective [26]. On the other hand, jaundice is not
frequently encountered in HFRS as compared with Weil's disease
[11. Thus, plasma exchange is not specifically indicated in HFRS,
and heparin and platelet transfusions are utilized only rarely [77].
Hemorrhagic fever viral infections can be approached by dif-
ferent therapeutic strategies: vaccination, administration of high-
titered antibodies, and antiviral drugs [78]. As the first two
approaches are not yet clinically available [79], the efficacy of
various drugs in the treatment of HFRS is under investigation.
For example, a combination of drugs including cytosine arabino-
side, aspirin, and cyproheptadine has been reported to be very
effective when administered early in the course of HFRS. During
this treatment, circulating levels of serum IgE and histamine
decreased dramatically [80].
Ribavirin(1-J3-D-ribofuranosyl-1,2,4-triazole-3-carboxamide, vi-
razole) was developed 22 years ago as a broad-spectrum antiviral
agent. Several compounds chemically related to ribavirin (tiazo-
furin, selanozofurin, ribamidine) have been reported as markedly
active against orthomyxoviruses, paramyxoviruscs, acenaviruses,
and bunyaviruses [78]. Since ribamidine is better tolerated than
ribavirin, the therapeutic indices of both compounds may be
similar. At present, ribavirin has proved effective in the treatment
of suckling mice infected with Hantaan virus. It is the only
antiviral chemotherapeutic drug known to have some benefit,
provided that the patient receives early treatment [78, 81]. A
2-year, double-blind, placebo-controlled efficacy trial of ribavirin
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for the treatment of epidemic hemorrhagic fever in China has
been completed [81]. This study examined nearly 300 acutely ill
patients and concluded that ribavirin was effective in preventing
death if its administration started on or before day 4 [5, 81]. The
drug also markedly reduced morbidity and frequently decreased
the time patients spent at each stage of illness. In addition,
antiviral treatment resulted in substantially reduced serum creat-
mine levels compared with those receiving placebo [5]. Ribavirin
is not effective in patients with advanced disease [78]. The only
adverse effect observed in patients treated with the drug was the
development of hemolytic anemia. This well-recognized side
effect is fully reversible upon cessation of the treatment [82, 83].
The primary target of the antiviral action of ribavirin was
originally identified as the enzyme ribose-phosphate inosine
monophosphate (IMP) dehydrogenase that converts IMP to
ribose-5-phosphate xanthosine-monophosphate (XMP). Thus,
GMP, GDP, and GTP pool levels are reduced, and viral RNA
synthesis is suppressed [84]. That ribavirin acts via depletion of
the intracellular GTP and dGTP pools is supported by the fact
that its antiviral and cytotoxic effects can be reversed by the
exogenous addition of guanosine but not by other nucleosides.
Finally, it can be phosphorylated to its 5 '-triphosphate and in this
form it can interfere directly with viral RNA synthesis, viral
mRNA capping guanylylation, and primer generation and elon-
gation during viral RNA transcription [85].
The study of potential immunomodulators as antiviral agents
for the treatment of viral hemorrhagic fevers could be important
because some viral infections are associated with rapid immuno-
suppression of the host [78]. For example, the nucleoside ana-
logue 7-thia-8-oxoguanosine (TOGuo) has been reported to have
broad-spectrum antiviral activity against several DNA and RNA
viruses [86]. When ribavirin was combined with TOGuo to treat
punta Toro virus infection in mice, the therapeutic index of
ribavirin was increased by decreasing toxicity and increasing
antiviral activity [87]. Thus, treatment of HFRS patients with
agents that block the production or action of various mediators
might provide information on the pathogenesis of the disease and
lead to improved management of patients during the acute phase
of the disease.
Epidemiologic studies in the U.S. have revealed that many
seropositive persons suffer from chronic renal disease and/or
arterial hypertension [88]. Consequently, it is possible that, as in
Patient 2, a small percentage of patients with HFRS do not
recover completely. In the long term, one could assume that
hantaviral infections might account for a percentage of chronic
renal disease and/or hypertension now considered idiopathic. If
this hypothesis is correct, one could assume that the acute phase
of the disease often goes unrecognized [26].
Prophylactic measures
The idea that infectious diseases are in decline must be
abandoned. Unprecedented social and ecologic changes increase
the likelihood of previously unidentified diseases appearing and of
old ones resurging [89]. Periodic reports from Europe, Asia,
North America, and Africa of new hantavirus isolates and new
cases point to other hantaviruses in geographically isolated rodent
populations. Thus, expanded surveillance of known vectors and
pathogen reservoirs is needed. Increased numbers of rural and
urban rodents reflect defective natural control, and this increase
might be due to the unusual profusion of their staple food
observed after heavy summer rainfalls.
The presence of indigenous rodents in abundance is confirmed
by most of the patients interviewed. In cold Scandinavia, the
prevalence of the disease peaks during the winter when rodents
seek food and shelter in the human habitat [3]. Farmers, wood-
cutters, and workers in these areas inhale aerosolized virus-
containing particles excreted through lung, saliva, urine, and feces
of the infected animals. This means that it will be impossible to
protect humans from the disease if they work in the area. For
researchers, wearing gloves and masks is mandatory while han-
dling laboratory rats. Ventilation of the rooms at the animal
facility should be adequate, and contaminated implements should
be sterilized by boiling or autoclaving [77]. In addition, early
diagnosis by accurate and sensitive assays using serologic methods
can prevent contamination of other persons working in the area
by alerting them to the risk from the infected rodents. Finally,
there is an urgent need for a safe and effective vaccine for
high-risk individuals so that HFRS can be controlled in endemic
areas [79]. Since 1984, extensive work has been under way, but
clinically useful vaccines are not yet available.
Questions and answers
DR. NIcoLAos E. MADIAS (Chief Division of Nephrology, New
England Medical Center, Boston, Massachusetts): First I would like
to ask Prof. Ho Wang Lee, the virologist who first isolated the
virus, to tell us his experience regarding the epidemiology of the
disease.
PROF. Ho WANG LEE (Asian Institute for Life Sciences, Seoul,
Korea): The discovery of the virus causing Korean hemorrhagic
fever in 1976, now called Hantaan virus, launched a new era in the
study of hemorrhagic fever with renal syndrome (HFRS) through-
out the world. Worldwide, 150,000 people are hospitalized with
HFRS each year; 3% to 10% of them die. Serologic studies of 57
hantaviruses isolated from HFRS patients and from animals
indicated that there are 6 or 7 serotypes [90]. Many HFRS
patients in endemic areas have been misdiagnosed as having
influenza, leptospirosis, scrub typhus, murine typhus, dengue,
hepatitis, interstitial nephritis, and even "acute abdomen." An
inactivated purified mouse brain Hantaan virus vaccine against
HFRS is available in Korea. Recently, simple and rapid serologic
diagnostic kits, the HDPA test, for Hantaan and Puumala virus
infections were developed. In the 1990s, it now is quite easy to
identify HFRS and HFRS-like illnesses caused by hantaviruses in
parts of the world where HFRS is not well known, given the
availability of these newer serodiagnostic tests.
DR. MAmAs: Professor Bautz, would you tell us your experience
on the molecular biology of hantaviruses?
PROF. EKKEI-IARD BAUTZ (Institute for Molecular Genetics, Uni-
versity of Heidelberg, Heidelberg, Germany): With the introduction
of recombinant DNA methodology, it has become possible to
decipher the primary structure of viral genomes. During the past
several years, the major strains of hantaviruses have been ana-
lyzed in molecular detail. All hantaviruses possess a tripartite
negative-strand RNA genome, with a coding capacity for (1) the
RNA replicase, (2) a precursor protein which, in vivo, is processed
into the Gi and G2 glycoproteins that form part of the membrane
surrounding, and (3) the nucleocapsid protein [91—93]. While the
glycoproteins are primarily responsible for eliciting the produc-
tion of neutralizing antibodies, the nucleocapsid protein is the
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most prominent antigen for diagnostic purposes. My colleague,
Prof. G. Darai at the Department of Medical Virology, and I have
therefore concentrated our initial efforts on producing recombi-
nant nucleocapsid protein in E. co/i and setting up an ELISA test
for the detection of IgG or 1gM antibodies [94], With these
techniques it has also become possible to determine the most
antigenic region of the protein that is concentrated primarily, but
not exclusively, in the N-terminal quarter of the molecule.
With an ELISA test set up with Nephropathia epidemica virus
(Puumala) and Hantaan-recombinant antigen (now commercially
available from Progen company in Heidelberg), we have—that is,
primarily Dr. Zoller at the Germany Army Hospital in Koblenz
and Drs. Kruger and Meisel at the Charite in Berlin— embarked
on a large epidemiologic study involving about 15,000 sera from
normal persons and from risk groups [95]. So far, in Germany
about 1.3% of the general population, depending on geographic
distribution, have IgG antibodies, primarily against Puumala
antigen. Risk groups, such as forest workers and animal caretak-
ers in hospital research facilities have a higher percentage of
positive sera. Because of this background level, it is necessary to
distinguish between old and new infections. To this end, we have
set up a p-capture ELISA assay that picks up new infections
exclusively. In the 18 months since this p-capture ELISA has
become available, the incidence of reported hantavirus infections
has drastically increased in those areas of Germany where the
local doctors have been alerted to the possibility of hantavirus
infections if they see patients with symptoms of HFRS [96].
DR. MAmAs: Prof. Bautz, what is the degree of homology
between the different strains of viruses? On the basis of their
structure, can you make any deductions on the possible evolution
of the viruses one to the other? Are there similarities of these
viruses with any other category of viruses? And last, what impli-
cations might the knowledge of this viral structure have for
therapy?
PROF. BAUTZ: That's a bundle of questions. Let me address the
first one on homology. Hantaviruses are typical RNA viruses, in
the sense that their mutation rate is very high. They evolve very
quickly to other strains. For instance, the differences between
Hantaan and Puumala at the protein level are about 50%. The
end segments of the genome of all bunyaviridae are very much
conserved, which means that they probably are very important for
replication. There are also homologies to other bunyaviruses,
where the large fragments coding for the viral replicase have
certain conserved sequences. This is expected since they all have
the same function, namely, replication of RNA for which the ends
of the RNA are very important. There are a lot of questions in
other areas of medicine about so-called anti-sense therapies. That
is, if you want to inhibit an enzyme, you allow the cell to make
anti-sense RNA. If one could make this anti-sense RNA stable
and infectious, one could utilize oligonucleotides to inhibit viral
replication.
DR. EUSTATHIOS ALEXOPOULOS (Department of Nephrology, Hip-
pokration Hospital): Dr. Papadimitriou, your second patient did
not fully recover from his renal failure, even after a prolonged
period. His second renal biopsy, apart from showing some chronic
changes, contained evidence of an active interstitial infiltrate. Did
cell-mediated immune mechanisms play a role in the progression
to chronic renal failure in this patient with hantavirus infection?
DR. PAp&DIM!TRIou: Cellular mechanisms are active in hanta-
virus nephropathy in addition to humoral mechanisms. We were
indeed surprised that this patient presented after some years with
evidence of chronic renal failure. As I said, we did not have any
interim complaints or lab investigations, but these lesions could be
nonspecific. For example, in postpartum renal failure, there are
instances in which the patient recovers, at least partially, and then
returns after some years with hypertension and renal failure. A
likely reason is that focal intravascular coagulation in the kidney
produced regional renal ischemia and resulted in a vicious cycle of
hypertension and consequent renal disease. Of course, one can
identify the lymphoid population by monoclonal antibodies and
see what is happening as far as the cell type is concerned, and I am
sure this is worthwhile.
DR. MADIAS: I would like to pursue this issue. Obviously it is
very important whether the disease can really evolve into a
chronic condition with clinical consequences. Perhaps Dr. LeDuc
could tell us his experience.
DR. JAMES LEDUC (Microbiology and Immunology Support Ser-
vices, World Health Organization, Geneva, Switzerland): May I first
say a few words about what happened recently in the U.S.? Over
the past decade or more, investigations into the epidemiology of
Seoul virus in domestic rat populations in Baltimore, Maryland,
have clearly demonstrated that rats in some neighborhoods were
heavily infected. The virus was repeatedly isolated, transmission
was demonstrated throughout the year among rats, and virtually
all the rats in the oldest age group were infected. Attempts to
determine whether the resident human population also was
becoming infected identified seropositive individuals and led to
the recognition of 3 serologically confirmed acute infections
among patients hospitalized at Johns Hopkins Hospital. Their
disease was similar to hantaviral infections described elsewhere,
including fever, generalized weakness, and epigastric pain. They
all suffered pleural effusions. Urinalysis indicated that all had
proteinuria, and 2 experienced both oliguria and polyuria. These
findings answer one question that has been of some concern for
several years, that being "Why don't we see human cases of
hantavirus infection in the United States?" Such infections un-
doubtedly have been present but simply not recognized because of
a lack of clinical suspicion and the absence of a reliable diagnostic
test.
To examine the association between Seoul virus infection and
hypertensive renal disease, three distinct Baltimore populations
were considered [97]. A reference group comprised serum spec-
imens from 6060 individuals who had presented to the emergency
rooms of area hospitals and had no other known risk factors
except living in Baltimore where infected rats are common. The
second group comprised 1766 patients of the Johns Hopkins
Hospital with proteinuria, and the third group comprised 254
patients receiving maintenance hemodialysis for end-stage renal
disease. When the seroprevalence rates for these two groups were
compared with that of the reference population, patients in the
clinical groups were significantly more likely to be seropositive as
compared with the reference group. The odds ratio between the
reference group and the proteinuric patients was greater than 3,
and the same comparison with the dialysis group found an odds
ratio of nearly 5. When the dialysis patients were examined to
determine their primary diagnosis, all those seropositive clustered
among the 40% of patients with a primary diagnosis of hyperten-
sive renal disease, and none was found among the other diag-
noses. This clustering was highly significant (P = 0.018). Thus, a
clear, specific association was found between past hantaviral
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infection and subsequent development of a specific chronic renal
disease. The association was statisically significant for hyperten-
sive renal disease only. Clearly these findings need to be con-
firmed by others. However, brief review of some recent studies on
hantaviral infections in Europe found that more than 10% of
patients surviving severe hemorrhagic fever with renal syndrome
(HFRS) had evidence of chronic renal insufficiency [981. As a
tr,emendous amount of money is spent annually on maintenance
of end-stage renal disease patients, there is a potential cost benefit
to confirming this suspected association.
DR. MMIAs: Let's continue with Dr. LeDuc's information.
Obviously, the possibility of hantavirus infection evolving into
chronic renal disease is of great interest. Regarding your point
that seropositivity in dialysis patients was only present among
patients with the "specific" diagnosis of primary hypertensive
renal disease, I should comment that the diagnosis of hypertensive
nephrosclerosis in a dialysis population is not always based on
rigorous criteria. Moreover, I do not think that the emergency
room patients represented an appropriate reference group for
that study. In my opinion, a better control would be people living
in the same household as the proteinuric and the dialysis patients.
Seropositivity might reflect the domestic conditions of these
individuals rather than implying causality regarding their renal
disease.
DR. LEDUC: I certainly agree that there are limitations on the
control population as well as on some of the clinical parameters.
We labeled this an association, and we did not say that it was a
direct causal association. I think our job as epidemiologists is to
make observations and then to draw attention, if you will, of the
experts to this potential problem. I have one comment: the
diagnoses that I listed as specific causes of renal insufficiency were
all made by nephrologists. I am not a nephrologist, and these
diagnoses were made without the knowledge by the nephrologist
of the serologic results. It was indeed a blinded effort.
DR. JAN P. CLEMENT (Queen Astrid Military Hospital, Brussels,
Belgium): As a nephrologist, I am as fascinated by the possibility
of Hantavirus-induced chronic renal disease as is Dr. Madias. To
return to the second case, again I have to question whether we are
really talking about progression of renal disease. The patient left
the hospital with a serum creatinine of 2.4 mgldl, and he returned
after an interval of 10 years with no documented interim data. His
followup serum creatinine was lower when compared with that
measured 10 years ago. It thus is very difficult to talk of progres-
sion of renal disease in this case.
DR. PAPADIMITRI0u: Let's look at the example of the progres-
sion of secondary hemolytic-uremic syndrome with partial cortical
necrosis. The patient is all right at discharge after recovering from
the acute illness, goes home, and comes back with a serum
creatinine level virtually normal in a couple of months. We do not
keep patients with a serum creatinine of 2.4 mg/dl in the hospital
if they feel all right. Despite the creatinine levels becoming almost
normal after some months, a few years later the patients return
with higher serum creatinine values. I believe this happens
because they already had ischemic changes in their kidneys that
produced a syndrome with proteinuria and hypertension. Finally
they enter the terminal stage of chronic renal disease. This is only
my hypothesis for this patient, because, as pointed out, unfortu-
nately we do not have interim data. This case is probably a
nonspecific case, not due to Hantaan virus itself, but due to
nephrosclerosis with undetected high blood pressure for a long
time.
DR. MADIAS: I would like to know whether Prof. Lee or anyone
else in the audience has any information on patients with HFRS
going into a chronic phase of renal dysfunction. I am not bothered
by somebody leaving the hospital with a serum creatinine of 2 or
3 mgldl. We know that over the following few weeks, the level can
normalize, The issue is whether you have information that any of
these patients can develop chronic renal insufficiency that is
otherwise unexplained.
DR. LEE: The issue is the sequelae after the acute renal
syndrome in this patient. There are not many long-term followup
studies, but unfortunately or fortunately 8 of our laboratory staff
were infected with Hantaan or Seoul virus in the animal lab during
1977 to 1981; 4 of them are still working with me, and all are
complaining of general symptoms at work (tiredness, low-grade
fever, backache). One of them has some renal dysfunction, but we
do not know whether he had this dysfunction before the HFRS
infection.
DR. MADIAS: Dr. LeDuc, since the military population is very
well followed, I would be interested in knowing whether any
information is available on them. For example, what is the current
status of the 3000 United Nations soldiers who developed HFRS
during the Korean war? Did any of them develop chronic renal
disease later?
DR. LEDUC: We have been trying to do that very study for many
years. In fact, it is now being done by a veterans medical followup
agency. Unfortunately, I have no results to relate to you, but there
is a very good data base on patients who were involved during the
Korean War. We have looked at sera from those patients and
have confirmed that more than 90% of the clinical diagnoses were
accurate. These records are available for followup analysis.
DR. CLEMENT: Another study in a military population looked at
seropositivity in 7123 individuals who submitted to IgG IFA
testing for Hantaan virus, Puumala type. We found overall figures
similar to those in Germany. Like Prof. Bautz, who cited other
European series, we found a serum prevalence of approximately
1% [991. Note that we performed extensive renal examination
including renography and renal function tests on 40 subjects. Not
only was the clinical history negative, but the whole renal picture
was absolutely within normal limits. I also followed 5 patients with
serologically proven Puumala virus infection up to five years and
submitted them to a series of tubular function tests, because
tubular dysfunction is the first to appear and the last to return to
normal. The only abnormality I could find—but I stress it was only
5 patients—was that 2 of them had a deficit in concentrating
ability.
DR. MADIAS: I think we will find very few cases of chronic renal
disease, unless a patient develops cortical necrosis. But given the
fact that this virus attacks endothelium so intensively, I would
have expected hemolytic-uremic syndrome to be more prevalent.
Have you seen much in terms of schistocytes, hemolysis, or fibrin
thrombi on biopsies? Has anyone reported patients with severe
intravascular coagulation who have survived and developed cor-
tical necrosis?
DR. PAPADIMITRIOU: Some reports have concluded that long-
term residual renal injury can occur in patients with HFRS [28,
100—102]. The reports looked at soldiers who contracted the
disease during the Korean war [100] and a more recent group
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[102]. There is no doubt that a small percentage of the patients
with acute renal injury later develop chronic injury.
DR. MADIAS: But do these patients have active HUS, that is,
schistocytes, helmet cells, and hemolysis?
DR. PAPADIMITRI0U: Yes, those findings were present during the
acute phase of the disease. We also saw such patients, but these
particular series I talked about were followed for several years
[100—1 02].
DR. CHRI5T0s SYRGANIS (Department of Nephrology, Hippokra-
tion Hospital): Dr. Lee, what is the specificity and sensitivity of
current diagnostic methods for HFRS?
DR. LEE: We currently have a number of serologic tests for the
diagnosis of Hantaan virus infection: immunofluorescent antibody
technique, immunosorbent methods, hemagglutination inhibition,
immune-adherence hemagglutination and enzyme immunoassay
(ELISA) tests. One of our colleagues recently developed a test
with the Western blot method, although it is not yet commercially
available. And of course there is an ELISA test. Among these the
immunofluorescent and ELISA tests have long been the most
commonly employed. The ELISA test is more sensitive than is
immunofluorescence, so if you demonstrate 1gM antibody against
hantavirus, you make the serologic diagnosis. Among the other
techniques, the high-density-particle agglutination test is very
simple and rapid, called the IgG/IgM capture enzyme immunoas-
say method; this kit is available now. The Hantaan high-density
agglutination particle is available commercially in our country and
in Japan, and the very sensitive Puumala virus high-density
particle agglutination kit that we developed will be available soon.
The other serologic tests are time consuming and very expensive.
PROF. PANOS METAXAS (Director of 2nd Propedeutic Department
of Medicine, Hippokration General Hospital): As an elder internist
rather than nephrologist, let me say that HFRS appears to
resemble the old streptococcal infections and the poststreptococ-
cal sequelae, such as acute nephritis and rheumatic fever. Now we
have a group of viruses causing a diverse disease in which the
target organ is predominantly the kidney or the lung; this reminds
me of Goodpasture's syndrome. The variability of the disease is
not surprising, because as with streptococcal infections, we have a
phase of acute infection due to the virus itself, and a postinfec-
tious phase characterized by the endothelial damage, that is, a
type of endotheliosis. Now we wonder whether the kidney sustains
residual damage after the acute phase has passed. Hippocrates
said that if damage is done to kidney cells, they can never recover
to normal. It might appear that there has been no residual
damage, but I think that even in the uncomplicated cases of acute
renal failure, silent damage flares up later as renal failure because
of a decreased number of nephrons. Besides, the fact that chronic
hemodialysis patients have a high percentage of seropositivity to
Hantavirus shows that there were instances of renal failure that
progressed unnoticed. I am impressed by the high percentage of
patients in Dr. LeDuc's U.S. data who progressed to renal failure
undiagnosed. Since the primary disease is infectious in origin,
certainly the whole inflammatory process must be involved,
including release of various cytokines. Has anyone investigated
any of these cytokines? Has there been any attempt to define
them? Second, have corticosteroids been used to see whether the
course of the disease can be altered?
DR. PAPADIMITRJ0u: Let me reply to your second question first.
Cyclophosphamide has been used in the second phase of the
disease with some success according to one Chinese series [76]. In
addition, antiallergic protocols with cyproheptadine and small
doses of corticosteroids produced good results [761. These results
have not been confirmed by others, however.
Cytokines have been measured in the acute phase. Also, we
know that T-cells are activated. The problem is that the suppres-
sor cells are also increased, so the T41T8 ratio is decreased, as in
patients with AIDS. During the acute phase of the disease, the
patient is overimmunosuppressed. So Prof. Metaxas is right to
wonder about these kinds of problems.
DR. CLEMENT: The Chinese literature contains evidence of an
enormous stimulation of the release of cytokines, and part of the
disease's symptoms might in fact be cytokine-induced. We discov-
ered one very surprising feature by coincidence during the Belgian
epidemic: most of the patients in the acute phase had suppressed
cholesterol levels and very elevated triglyceride levels. One might
think that this has nothing to do with cytokines, but in recent
reports triglycerides have been used as an indirect bioassay for
TNF, interleukin-1, and IL-6 [103], They even have been used as
an activity parameter in the followup of AIDS patients during
treatment. So elevated triglycerides might be indicative of in-
creased cytokine activity. In the Belgian patients, the very elevated
triglyceride levels have fallen after a couple of days or a maximum
of two weeks.
DR. SYROANIS: Dr. Bautz, have viral antigens been detected in
various organs? Have the Hantaan virus or the viral genome been
detected in human renal tissue or other tissues?
DR. BAUTZ: Dr. Schmidt from Hamburg reported that PCR
disclosed Hantaan virus fragments in a renal biopsy specimen
from a patient in the acute phase of the disease (personal
communication). Another study from Berlin, in collaboration with
us, reported a viral fragment by PCR in renal biopsy material from
primates (Kruger, personal communication). We tried to repeat
the result with the same material and the same PCR primers, but
we could not confirm it. Thus, it is possible that the latter finding
represented a false-positive result with the PCR reaction.
DR. MADIAs: I have a question about the recently described
American epidemic. Dr. LeDuc, is it your impression that we are
dealing with a new strain of virus of extreme virulence that has
developed recently, or do you think that the virus' infectivity has
been stimulated by new ecologic situations? Why do you think
that so many people have developed such an aggressive disease in
such a short period?
DR. LEDUC: That is a very interesting question. I think the
situation in the U.S. is not new; the virus probably has been
present in a smaller population for a considerable length of time.
I think that a confluence of environmental and ecologic conditions
resulted in a dramatic increase of the rodent population. The
humans most affected were people living or working near those
rodents, and consequently they were the ones who became
infected. Once we recognized this clinical syndrome, the tremen-
dous amount of publicity that resulted allowed clinicians to recall
isolated cases seen several years earlier. We had a very interesting
patient with disease of unknown cause. When we went back and
looked at his tissue and serum specimens, we realized that this
man in fact had hantavirus infection. We also know that there
were positive rodent tissues at least 10 years ago in his environ-
ment.
DR. MAmAS: What is the Belgian and the Greek experience
with the disease?
PROF. CLEMENT: During the most important outbreak so far of
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hantavirus nephropathy in Belgium, a total of 62 serologically
proven cases were registered (from July 1992 through January
1994) in the southern Ardennes [104]. Immunofluorescence assay
screening for IgG established a significantly higher mean geomet-
ric titer for the "European" serotype Puumala than for Hantaan
serotype. ELISA for p-capture 1gM confirmed Puumala as the
serotype involved in all samples from patients with acute disease.
We noted some interesting environmental factors: a very dense
local population of bank voles (the main rodent vector for PUU),
an abundance of beechnuts (the staple food of voles), a rainy
spring and summer of 1993, and a mild 1992-1993 winter. With
antigen-capture ELISA, we found the presence of a PUU-like
antigen in a total of 10 of 163 (6%) voles trapped in June,
September, and November 1993 around the habitats of patients
with hantavirus nephropathy. All other rodent species captured (a
total of 94) were PUU-antigen negative. A total of 7 patients were
registered who presented with adult respiratory distress syndrome
(ARDS) or its less severe form called AL! (acute lung injury),
together with a variable degree of acute renal failure (peak serum
creatinine range, 1.7 to 10.4 mg/dl). They all presented with fever,
arterial desaturation (Pa02 range, 39.0 to 74.5 mm Hg corrected
for 37°C), and tachypnea (PaCO2 range, 24 to 32 mm Hg); 3 of 7
also developed diffuse bilateral interstitial pulmonary infiltrates.
Combined dialysis and mechanical ventilation were necessary in 2
patients; one presented with fluid overload; the other presented
with shock (blood pressure, 65/40 mm Hg), diffuse intravascular
coagulation, internal hemorrhages, and ARDS (P02, 39 mm Hg;
PaCO2, 28 mm Hg) [105]. Thus European PUU-induced hanta-
virus nephropathy can present with ARDS, a feature hitherto
considered specific for the current hantavirus epidemic in the U.S.
DR. ANTONIOS ANTONIADIS (Department of Microbiology, Aristo-
telian University of Thessaloniki): Hemorrhagic fever with renal
syndrome is endemic in Greece. A survey between 1981 and 1993
revealed that antibodies against Hantaan virus are found through-
out Greece, with an overall antibody prevalence rate of 4%, with
a range from 0% to 14%. The maximum percentage of positivity
occurred in areas where clinical disease was diagnosed. Small-
mammal serosurveys conducted in areas where HFRS was diag-
nosed revealed that the vertebrate host of the virus causing severe
HFRS in Greece is Apodemus flavicollis. A Hantaan-like virus
(Porogia virus), which is serologically more closely related to
Hantaan than to Puumala virus, was isolated from the urine of a
severely ill patient with HFRS [11]. Between 1982 and 1994, 138
cases of HFRS were serologically diagnosed in rural populations
of Greece [26]. The disease in Greece more closely resembles the
Asian form of HFRS than the Scandinavian and western Euro-
pean form of the disease because of the high mortality rate (9%),
the occurrence of hemorrhagic manifestations, and the severity of
the clinical disease. Of 138 serologically diagnosed cases, 12
(---9%) died and 30% required dialysis [26].
DR. STAVROS EFREMIDIS (Department of Radiology, Hippokration
Hospital): It was stated several times that the pulmonary edema is
not cardiogenic in origin. What is the likely cause of the pulmo-
nary edema? Patients with bilateral lung opacities died immedi-
ately after admission. Were pathology reports obtained on these
patients? Was the major feature of this edema hemorrhagic, or
did it have a high protein concentration?
DR. MMIAs: I have a similar question. In several publications I
have read that some patients develop bradycardia. In other
situations, people had severe hypotension. My specific question is
whether there has been pathologic evidence of myocarditis in
some of these people.
DR. CLEMENT: In Korean cases, hemorrhagic myocardial dam-
age was found [106]. It is a fact that hantavirus disease is one of
the few infectious diseases, together with typhoid fever and
legionella, that can present with bradycardia despite the feverish
condition; the first patient presented here also had bradycardia.
As a matter of fact, our very first patient in Belgium more than 10
years ago was monitored by cardiologists because, despite his
fever of more than 40°C, he had persistent sinus bradycardia of 40
beats/mm. But, to be honest, beyond transient myocarditis I do
not have an explanation for this phenomenon.
DR. ALExoPouLos: Does the presence of specific antiviral
antibodies protect the patient from subsequent insult? In other
words, what is the rate of reinfection? Also, does vaccination have
adverse sequelae?
DR. LEDUC: I am not aware of any cases of double infections.
I think that a patient who has survived is protected for life.
DR. LEE: I agree with Dr. LeDuc. As far as I know, there is no
evidence of reinfection from this disease. You ask about untoward
reactions of the vaccine. The vaccine has been available since
1991, and one to two million people are vaccinated annually. Last
year a serious problem occurred, but we did not know whether it
was a reaction from the vaccine. Patients developed a very
allergic, erysipelas-like exanthema. There are quite a few adverse
reactions like those you see with the hepatitis B vaccine, such as
rash and fever. About 2% to 3% of vaccinees show such adverse
reactions, but in general there are no severe reactions from our
vaccine.
DR. MARIA LEONTSINI (Head, Department of Pathology, Hip-
pokration Hospital): Is there any pathogenetic relationship be-
tween Balkan nephropathy and the chronic form of Hantaan virus
disease?
DR. ANT0NIADIs: We have no evidence that the virus causes
Balkan nephropathy.
DR. MMs: How certain are we that HFRS is not transmitted
between people? I am specifically concerned about transfusions,
given the fact that you described so much seropositivity.
DR. LEDuc: Very good evidence indicates that there is no
person-to-person transmission of this disease. The most dramatic
data come from the Korean War. We had very closely studied
cases and a large number of cases, and we did not use the best
preventive techniques. Yet we did not see a single case of
secondary infection. Likewise, there is no indication of secondary
or nosocomial transmission from patients with acute hantavirus
pulmonary syndrome.
DR. SYRuiu4Is: Anti-enthothelial cell autoantibodies have been
detected in patients with HFRS. Have other autoantibodies,
especially ANCA, been detected as well?
DR. CLEMENT: The few patients we have looked at were
negative for autoantibodies, such as ANCA, ANA, anti-smooth
muscle, etc. Besides, in one of the cases presented by Dr.
Papadimitriou, several autoantibodies tested were negative.
DR. MAJiiqAs: I would like to know a little more about the host,
the reservoir of the virus. How much do we know about their
infectivity, how do they shed the virus, and what type of disease do
they get?
DR. LEE: We did an extensive study on the role of the rodents
after infection with Hantaan and Seoul viruses. The Apodemis
mice get a chronic infection, the virus exists for at least one year,
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and they excrete the virus in the urine for about a year or so. The
Apodemis mouse actually is the best model of the Hantaan virus
carrier. In the rats the Seoul virus infection is less chronic than
that in the Apodemis. The virus exists for a couple of months, and
the excretion of the virus in the urine and saliva continues for less
than one month. The rats excrete no virus in the urine or saliva;
that is why we do not have many cases in the urban areas. We are
lucky in some way, because should rats excrete the virus in the
urine and saliva, as do bigger animals, the virus would have spread
immensely. In the voles with Puumala virus, the virus exists in the
lung for at least five months and is excreted in the urine and saliva
for a couple of months.
DR. PAPADIMITRI0u: Therefore we should prefer to have rats
than mice around us! I think we could summarize by saying that
the disease is emerging in almost every part of the world. More
information is needed concerning the epidemiology, pathogene-
sis, and treatment of an acute disease that can lead to acute
complications, and possibly to chronic renal injury, at least in a
small percentage of cases.
Reprint requests to Dr. M. Papadimitriou, Director, Division of Nephrology,
Hippokration General Hospita4 Thessaloniki 546 42, Greece
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